Redox (ASX:RDX) Shares Drift While Margins And Profit Keep Improving

Redox walked into this result with the stock down about 14% over the past week and about 13% over the past month, even though the longer 3 month line still showed a gain. That set the stage for a classic sentiment clash. The headline from the earnings is clear. Profit quality and margins are quietly tightening up while the market has been in de risk mode.

The key tension for you as an investor is simple. The share price has been marking time while earnings per share and net profit margin tell a more resilient story in the underlying distribution business.

Is Redox trading on a stretched 18.8x P/E multiple, or do the improved 6.9% margin and 19.2% earnings growth justify the current price? Compare the current share price against our valuation analysis for Redox.

FY 2026 Earnings Summary

• Revenue (FY 2026 vs FY 2025): A$1.33b vs. A$1.24b (up 6.9%)
• Net Income from Continuing Operations (FY 2026 vs FY 2025): A$91.9m vs. A$77.1m (up 19.2%)
• Basic EPS (FY 2026 vs FY 2025): A$0.175 vs. A$0.147 (up 19.2%)
• Net Profit Margin (FY 2026 vs FY 2025): 6.9% vs. 6.2% (improved by 0.7 percentage points)

Tired of wading through dense earnings releases and spreadsheets to work out what really changed for Redox this year? Get a clear visual view of Redox’s margins, earnings trends and valuation in the full company report for Redox.

Redox bull case: margins, mix and cash discipline

Bulls argue that Redox can turn specialty mix, digital systems and North American expansion into steady margin gains and higher returns. The FY26 print gives that view some support. Revenue rose 6.9% to A$1.33b while gross profit grew faster at A$298m and gross margin moved to 22.4%. EBITDAFX margin edged to 10.1% and ROIC reached 14.6%. That points to better mix and pricing rather than just volume. North America grew 33.8% to above A$100m and management highlighted higher margin activity there, which is exactly what the thesis wants to see. Cash generation held up with A$88m operating cash and 62.5% free cash flow conversion, even as opex increased A$19m to A$176m to support growth. A 74% payout ratio and net cash of A$123m suggest Redox is still funding both dividends and an M&A pipeline without stretching the balance sheet.

Redox bear case: cost creep, working capital and execution risk

The bear view focuses on margin pressure from cost inflation, working capital drag and the risk that acquisitions and North America do not translate into durable profit growth. FY26 results do not fully validate those concerns, but they also do not remove them. Underlying opex increased by A$19m as Redox added headcount and absorbed higher distribution, fuel and wage costs. Margin metrics still improved, so that cost creep has not yet squeezed earnings, but it is something you must keep watching. Net working capital sits at A$417m or 31.4% of revenue. Management calls this within the long term range, yet it keeps a lot of cash tied up in inventory and receivables. The New Zealand human health client loss shows customer concentration pockets can hurt. Management is also leaning harder into North American growth and bolt on deals, which raises the importance of disciplined integration and pricing as conditions shift.

With working capital at A$417m and net cash of A$123m tied into Redox’s growth plans, you need to verify how much balance sheet flexibility really exists. Check the full financial health analysis of Redox stock.

Stay Ahead With Simply Wall St

If the mix of margin gains, cash generation and growth plans at Redox has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you own the stock, keep focused on what really matters by using the Portfolio Command Center to cut through noise and surface only the key developments on earnings, cash flow and balance sheet strength. For a longer term view, use the Community to see how other investors are thinking about Redox and similar stocks. This combination helps you identify potential catalysts and monitor emerging risks so you can stay ahead of the wider market.

Seeking Alternatives Beyond Redox?

Fresh ideas can move before anyone notices. Use this momentum to find stocks that could be building toward a breakout while it matters and get in early.

• Scan for resilient balance sheets that can keep funding growth even when conditions shift by reviewing the curated list of solid balance sheet and fundamentals stocks (20 results).
• Spot income opportunities that might help stabilise your portfolio as prices swing by checking the hand picked 6 dividend fortresses.
• Hunt for under the radar quality stocks that may not stay mispriced for long by working through the focused 11 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com